Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 6, 2018

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2026

Conditions

Bone Marrow Transplant ComplicationsGraft Versus Host DiseaseInfection ViralEngraft FailureImmunologic Suppression

Interventions

DRUG

Cyclophosphamide

Cyclophosphamide 1000 mg/flask

DRUG

ATG

Antihuman T-Lymphocyte Immune Globulin 25 mg/flask

Trial Locations (1)

RECRUITING

Hospita Israelita Albert Eintein, São Paulo

All Listed Sponsors

lead

Hospital Israelita Albert Einstein

OTHER